Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study

BACKGROUND: Angiogenesis is a hallmark of head and neck squamous cell carcinoma (HNSCC), and a mechanism of resistance to EGFR inhibition. We investigated the safety and potential activity of pazopanib, an angiogenesis inhibitor, plus cetuximab, an EGFR inhibitor, in patients with recurrent or metas...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Adkins, Douglas, Mehan, Paul, Ley, Jessica, Siegel, Marilyn J, Siegel, Barry A, Dehdashti, Farrokh, Jiang, Xuntian, Salama, Noha N, Trinkaus, Kathryn, Oppelt, Peter
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6561471/
https://ncbi.nlm.nih.gov/pubmed/30001987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30350-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados